Quantcast

Latest Aromatase inhibitor Stories

2010-10-12 14:14:16

Use of estrogen therapy is associated with an increased risk of developing kidney stones in postmenopausal women, according to a report in the October 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. "Nephrolithiasis [kidney stones] is a common condition that affects 5 percent to 7 percent of postmenopausal women in the United States," according to background information in the article. "Because the process of kidney stone formation is influenced by a variety of...

2010-10-11 13:13:38

Researchers at the University of Illinois at Chicago College of Medicine have found how gene expression that may contribute to drug resistance is ramped up in unusual types of breast tumors. Their findings may offer new therapy targets. The study is published in the Oct. 8 issue of the Journal of Biological Chemistry, where it is designated a paper of the week. Approximately 70 percent of breast cancers express the estrogen receptor. These "ER-positive" tumors usually respond to...

2010-09-23 12:02:22

A new study published in the Journal of Sexual Medicine looked at whether women were more likely to experience sexual problems after breast cancer. The results showed that 70% of women were facing sexual function problems approximately two years post diagnosis. Mary Panjari, PhD, of the Women's Health Program at Monash University, reported on the sexual well-being nearly two years after diagnosis and initial treatment of participants in the BUPA Foundation Health and Wellbeing after Breast...

2010-08-19 11:30:00

MENLO PARK, Calif., Aug. 19 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company. Further clinical development will focus on the lead compound's registration for the treatment of tamoxifen and aromatase inhibitor-resistant breast...

2010-06-30 08:39:08

A new study of nearly 8,800 women with early-stage breast cancer found that fewer than half "“ approximately 49 percent "“ completed their full regimen of hormone therapy according to the prescribed schedule. Investigators found that younger women were particularly likely to discontinue treatment. The findings underscore the need to both better understand the reasons behind such treatment non-compliance and also develop interventions to reduce it. "We were surprised to see that so...

2010-06-16 23:23:56

Women taking tamoxifen for early-stage breast cancer who developed blood clots were more likely to carry a gene mutation for clotting than women taking tamoxifen who did not develop blood clots, according to an online study published June 16 in The Journal of the National Cancer Institute. Tamoxifen is a widely-used breast cancer treatment after surgery for pre and post menopausal patients with hormone receptor-positive breast cancer. One of the most serious complications of tamoxifen usage...

2010-06-08 11:19:40

Study uses an investigational molecular imaging biomarker to determine how certain recurrent breast cancer patients will respond to therapy Research introduced at SNM's 57th Annual Meeting is expanding molecular imaging's role in determining the best course of treatment for recurring breast cancer patients, while offering a means of evaluating certain therapies for potentially positive impact on their chance of survival. "As the therapeutic arsenal against breast and other cancers continues...

2010-05-28 03:34:00

THOUSAND OAKS, Calif., May 28 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Prolia has been approved in all 27 European Union member states...

2010-05-10 08:53:19

A study by researchers from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) identifies a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant in estrogen receptor positive breast cancers. The findings are published May 15, 2010 as the cover story of Molecular Cancer Therapeutics. Fulvestrant is a common second-line therapy for women whose cancer progresses following anti-estrogen therapy. In this paper, Lombardi...

2010-03-30 13:55:00

An estrogenic drug that influences neurotransmitter and neuronal systems inthe brain is showing promise as an effective therapy for women who suffer from schizophrenia. A study has found that Raloxifene - a synthetic estrogen currently used to treat osteoporosis - has beneficial effects on postmenopausal women with schizophrenia, with a test group experiencing a more rapid recovery from psychotic and other symptoms compared to control groups. Research project leader and Director of the Monash...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related